CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jan. 31, 2025	Jan. 31, 2024	Jan. 31, 2025	Jan. 31, 2024
EXPENSES
Accretion expense	$ 128,836	$ 19,409	$ 158,695	$ 49,522
Consulting	66,784	113,600	121,890	166,183
Directors' fees	20,000	30,000	50,000	58,022
Filing and regulatory	11,923	8,679	35,920	21,586
Foreign exchange (gain) loss	3,286	(5,088)	5,413	7,899
General and administrative	50,606	116,992	124,972	262,151
Geological, mineral, and prospect costs	20,691	34,241	65,853	395,766
Interest expense	68,916	66,118	165,116	129,661
Professional fees	124,693	257,737	225,574	595,278
Promotion and shareholder communication	6,196	23,468	14,383	43,479
Salaries	0	5,268	0	89,569
Share-based compensation	36,211	140,624	198,719	230,985
Loss	(538,142)	(811,048)	(1,166,535)	(2,050,101)
Gain on fair value adjustment on derivative liability	0	211,196	0	128,715
Loss on note receivable	(155,727)	(126)	(155,727)	(64,564)
Other income	7,536	2,492	7,536	10,039
Net loss and comprehensive loss for the period	$ (686,333)	$ (597,486)	$ (1,314,726)	$ (1,975,911)
Basic loss per common share	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.05)
Diluted loss per common share	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.05)
Weighted average number of common shares outstanding (basic) (in shares)	55,785,106	44,636,253	55,785,106	42,499,527
Weighted average number of common shares outstanding (diluted) (in shares)	55,785,106	44,636,253	55,785,106	42,499,527